Royal Bank of Canada
QTTB icon

Royal Bank of Canada’s Q32 Bio QTTB Stock Holding History

Royal Bank of Canada’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
2,744
+2,509
+1,068% +$11.9K ﹤0.01% 5958
2025
Q4 		$1K Sell
235
-818
-78% -$2.31K ﹤0.01% 7069
2025
Q3 		$2K Sell
1,053
-5,265
-83% -$10.1K ﹤0.01% 6926
2025
Q2 		$10K Buy
6,318
+4,630
+274% +$7.89K ﹤0.01% 6490
2025
Q1 		$3K Buy
1,688
+305
+22% +$821 ﹤0.01% 6537
2024
Q4 		$5K Buy
1,383
+673
+95% +$21.3K ﹤0.01% 6558
2024
Q3 		$32K Buy
710
+88
+14% +$3.23K ﹤0.01% 5897
2024
Q2 		$11K Buy
622
+567
+1,031% +$13.6K ﹤0.01% 6314
2024
Q1 		$1K Buy
55
+37
+206% +$510 ﹤0.01% 6890
2023
Q4 		$0 Buy
+18
New +$263 ﹤0.01% 7665
2023
Q3 		– Sell
-185
Closed -$3K – 7692
2023
Q2 		$3K Buy
185
+102
+123% +$1.83K ﹤0.01% 6814
2023
Q1 		$1K Sell
83
-3
-3% -$75 ﹤0.01% 6950
2022
Q4 		$2K Buy
86
+23
+37% +$610 ﹤0.01% 6957
2022
Q3 		$1K Hold
63
– – ﹤0.01% 7300
2022
Q2 		$2K Sell
63
-210
-77% -$7.17K ﹤0.01% 7011
2022
Q1 		$15K Sell
273
-296
-52% -$18.4K ﹤0.01% 6771
2021
Q4 		$37K Buy
569
+350
+160% +$34K ﹤0.01% 6541
2021
Q3 		$32K Buy
219
+35
+19% +$4.46K ﹤0.01% 6431
2021
Q2 		$24K Sell
184
-199
-52% -$24.8K ﹤0.01% 6475
2021
Q1 		$65K Buy
383
+172
+82% +$36.2K ﹤0.01% 5726
2020
Q4 		$43K Hold
211
– – ﹤0.01% 5728
2020
Q3 		$41K Sell
211
-667
-76% -$149K ﹤0.01% 5429
2020
Q2 		$240K Buy
878
+761
+650% +$203K ﹤0.01% 4318
2020
Q1 		$33K Sell
117
-145
-55% -$44.4K ﹤0.01% 5342
2019
Q4 		$97K Buy
262
+205
+360% +$58.7K ﹤0.01% 5099
2019
Q3 		$19K Sell
57
-165
-74% -$56.1K ﹤0.01% 5527
2019
Q2 		$78K Buy
222
+166
+296% +$65.2K ﹤0.01% 5023
2019
Q1 		$28K Hold
56
– – ﹤0.01% 5494
2018
Q4 		$22K Sell
56
-24
-30% -$9.08K ﹤0.01% 5552
2018
Q3 		$33K Buy
80
+24
+43% +$8.15K ﹤0.01% 5433
2018
Q2 		$20K Buy
+56
New +$20K ﹤0.01% 5539

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada's QTTB Position: Q1 2026 in Review

Royal Bank of Canada increased its Q32 Bio (QTTB) stake by 1,068% in Q1 2026, buying an estimated $11.9K and bringing the position to 2,744 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #5958.

Royal Bank of Canada first reported a position in QTTB in Q2 2018 and has held it in 31 quarters since. The position peaked at $240K in Q2 2020. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Royal Bank of Canada held 2,744 shares of Q32 Bio worth $18K as of Q1 2026.
  • Royal Bank of Canada bought 2,509 Q32 Bio shares in Q1 2026, an estimated $11.9K.
  • Q32 Bio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5958 holding.
  • Royal Bank of Canada first reported a position in Q32 Bio in Q2 2018 and has held it in 31 quarters since.
  • Royal Bank of Canada's Q32 Bio position peaked at $240K in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.